|
Jul 24
|
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
|
|
Jul 17
|
Ligand Pharmaceuticals Stock Earns 84 RS Rating
|
|
Jul 16
|
3 Stocks That Might Be Undervalued And Present An Investment Opportunity
|
|
Jul 16
|
First Solar And 2 Additional Stocks That May Be Priced Below Estimated Value
|
|
Jul 2
|
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
|
|
Jul 2
|
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
|
|
Jul 1
|
Inter & Co And 2 Other Stocks That May Be Trading Below Estimated Value
|
|
Jun 30
|
3 Companies That May Be Trading Below Their Estimated Value
|
|
Jun 30
|
3 Prominent Stocks Estimated To Be Trading At Up To 38.9% Below Intrinsic Value
|
|
Jun 27
|
3 Stocks Estimated To Be Up To 48.8% Undervalued Offering A 32.6% Discount Opportunity
|
|
Jun 27
|
Three Stocks That May Be Trading Below Their Estimated Value In June 2025
|
|
Apr 17
|
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
|
|
Apr 17
|
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
|
|
Mar 3
|
Ligand to Participate in March Investor Conferences
|
|
Mar 3
|
LGND: First Steps into Cell & Gene Therapy
|
|
Feb 28
|
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Feb 27
|
Ligand: Q4 Earnings Snapshot
|
|
Feb 27
|
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 25
|
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
|
|
Feb 13
|
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
|